| tarcocimab tedromer (KSI 301) / Kodiak Sciences |
ChiCTR2100053500: Canceled by the investigator A Prospective, Randomized, Double-Masked, Active Comparator-Controlled, Multi-Center, Two-Arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-Naive Diabetic M |
|
|
| Not yet recruiting | 3 | 150 | | Intravitreal injection of KSI-301 (5mg) ;Aflibercept 2 mg intravitreal injection | Kodiak Sciences China Inc; Beijing Tongren Hospital Affiliated to Capital Medical University, self-funded | Diabetic Macular Edema | | | | |
ChiCTR2100053499: A Prospective, Randomized, Double-Masked, Active Comparator-Controlled, Multi-Center, Two-Arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion (RVO) |
|
|
| Suspended | 3 | 170 | | Intravitreal injection of KSI-301 (5mg) ;Intravitreal injection of aflibercept 2mg | Kodiak Sciences China Inc.; Beijing Tongren Hospital Affiliated to Capital Medical University, self-funded | Macular Edema Secondary to Retinal Vein occlusion | | | | |
BEACON, NCT04592419 / 2020-001061-37: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) |
|
|
| Completed | 3 | 568 | Europe, US, RoW | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Macular Edema, Retinal Vein Occlusion | 06/22 | 01/23 | | |
DAYLIGHT, NCT04964089 / 2021-000225-27: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) |
|
|
| Completed | 3 | 557 | US | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Wet Age-related Macular Degeneration | 03/23 | 04/23 | | |
| Terminated | 3 | 459 | Europe, US, RoW | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Diabetic Macular Edema | 04/23 | 08/23 | | |
| Terminated | 3 | 460 | Europe, US | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Diabetic Macular Edema | 05/23 | 08/23 | | |
| Terminated | 3 | 253 | Europe, US, RoW | KSI-301, Sham injection | Kodiak Sciences Inc | Non-proliferative Diabetic Retinopathy | 08/23 | 08/23 | | |
GLOW2, NCT06270836: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) |
|
|
| Recruiting | 3 | 250 | US | Tarcocimab, Tarcocimab tedromer, KSI-301, Sham injection | Kodiak Sciences Inc | Diabetic Retinopathy | 01/26 | 01/26 | | |
DAYBREAK, NCT06556368: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - |
|
|
| Recruiting | 3 | 675 | US | Tarcocimab tedromer, KSI-301, Tabirafusp tedromer, KSI-501, Aflibercept, Eylea | Kodiak Sciences Inc | Wet Age-related Macular Degeneration | 01/26 | 01/26 | | |
| tabirafusp tedromer (KSI-501) / Kodiak Sciences |
| No trials found |
| KSI-201 / Kodiak Sciences |
| No trials found |
| KSI-401 / Kodiak Sciences |
| No trials found |
| KSI-601 / Kodiak Sciences |
| No trials found |
